Medtronic Faces Insulin Pump Lawsuit as Sphere-9 and PulseSelect Registry Data Land

Fresh legal trouble has surfaced for Medtronic just as the company was showcasing clinical data from its cardiac ablation lineup. Two women filed suit on Tuesday, according to media reports, alleging that the device maker knowingly sold insulin pumps carrying a defect capable of delivering incorrect insulin doses. The claim puts litigation risk back on the radar for shareholders, running in parallel with — not counter to — the product momentum Medtronic has been building elsewhere.

What the Lawsuit Alleges — and What It Doesn't

The complaint concerns insulin pumps that the US Food and Drug Administration recalled in 2020. The distinction between the documented recall and the current allegations matters: the accusation of a knowing sale comes from the plaintiffs and has not been established in court. For investors, the central question is not merely whether the devices were technically reliable, but what Medtronic knew about the alleged defect. Whether that allegation holds up will drive any assessment of legal exposure — and the mere filing of the suit answers none of it.

A separate dispute occupied an appeals court the same day. A panel of judges on the Eighth Circuit voiced skepticism, per media reports, toward an attempt by investors to revive claims over allegedly concealed problems with a recalled insulin pump. The two matters should not be conflated. One involves two women suing over supposedly faulty devices; the other pits investors against the company over purportedly withheld information. The reported skepticism in the investor case says nothing about how the new lawsuit will be resolved.

MiniMed Spinoff Doesn't Close the Book

Medtronic wrapped up the separation of MiniMed roughly two weeks ago, retaining no MiniMed shares, according to the company. That corporate step and the legal evaluation of past conduct are separate questions. It would go too far for investors to read the completed exit as disposing of the newly filed claims — just as the lawsuit by itself does not establish liability.

Cardiac Ablation Registries Take Center Stage

On the product front, Medtronic presented positive registry data for its Sphere-9 catheter and PulseSelect PFA system at APHRS 2026. The two registries cover different products and emphasize different endpoints, so a split reading beats a single blended success rate. The APEX registry tracked 1,050 patients treated with the Sphere-9 catheter; the rate of serious complications came in at 1.1%, with Medtronic foregrounding the safety endpoint for that device.

The PulseSelect disclosure pairs acute efficacy with a safety metric also tied to the immediate phase — a distinction worth keeping in mind, since treatment success and complication rates describe different facets of a procedure. In the REAL-PULSE registry of 1,160 patients, Medtronic reported an acute treatment success rate of 100% and an acute serious complication rate of 0.09%. That success figure refers explicitly to the immediate outcome and is not a promise of long-term results.

These are clinical metrics, not business numbers. Revenue and earnings contributions cannot be derived from success rates and complication rates alone, and the differing figures should not be read as a direct head-to-head product comparison.

Vitalis Clears the Way Into Europe

Alongside the registry results, Medtronic received CE marking on Monday for its Vitalis portfolio, which comprises five pacemakers — including devices for stimulating the cardiac conduction system and for cardiac resynchronization therapy. The certification opens the door to marketing across Europe. The recent news therefore spans distinct milestones: European market access for Vitalis, real-world clinical data for Sphere-9 and PulseSelect, and now a lawsuit that keeps legal uncertainty in play.

The stock gained 3.2% on the day of the registry announcement, though no direct link between the share move and the company's disclosure has been established. What matters for sizing up the new complaint is whether the alleged defects and the claim of a knowing sale are substantiated — not simply that a case has been filed.